Good morning, you're tuned into Markets Desk.
Fast Retailing, the Japanese parent of Uniqlo, posted a strong close to its fiscal year ended August thirty-first, two thousand twenty six, with profit attributable to shareholders climbing twenty-five point three percent to five hundred forty-two point five billion yen. Diluted earnings per share came in at one thousand seven hundred sixty-five point seven yen, a result that underscores the brand's continued pricing power and global expansion momentum.
Shifting to biotech, argenx reported positive Phase two results for its compound FB one-oh-two in celiac disease, a meaningful win for the Belgian immunology firm. However, the company simultaneously announced it would discontinue its Phase three UNITY trial of efgartigimod in Sjögren's disease, a mixed session for the pipeline that investors will be weighing carefully against each other.
And in the tech space, European markets are bracing for a softer open after the Wall Street Journal reported that SpaceX, Broadcom, and Oracle are in discussions to raise capital specifically to purchase AI chips. The concern on the floor is whether anticipated AI infrastructure demand is already being priced ahead of actual returns, rattling sentiment across the Atlantic before the bell.
That's the tape. Markets Desk, signing off the floor.
